GLP-1 drugs in perimenopause: what the science actually says

What did @thecharlottemathis actually say?

The creator cited a review paper from Current Opinion in Obstetrics and Gynecology and made a sweeping claim: GLP-1 receptor agonists are "hands down 100%" the best way for perimenopausal and postmenopausal women to manage their weight. She also acknowledged a significant gap in the research, noting that no dedicated clinical trials have studied these medications specifically in this hormonal population. That tension between the bold endorsement and the admitted lack of data is exactly what needs unpacking.

She correctly identified the physiological drivers behind menopausal weight gain: estrogen decline leading to increased visceral adiposity, worsening insulin resistance, and elevated cardiovascular risk. These are real, well-documented mechanisms. The call to action at the end, asking viewers to comment "peptide" for resources, signals she is likely directing followers toward compounded peptide products, which is worth flagging.

Does the science back this up?

Partially, but the "hands down 100%" framing overstates what the evidence actually supports. The review paper she references, likely Banaszewska et al. or a similar 2023-2024 narrative review in that journal, does not conclude GLP-1s are definitively superior for this population. It calls for more research precisely because the evidence base is thin.

What we do know comes from subgroup analyses, not dedicated trials. In the SCALE trials for liraglutide and the STEP trials for semaglutide, postmenopausal women were included but not analyzed as a primary subgroup with enough statistical power to draw firm conclusions. A 2023 analysis by Sarma et al. in Menopause noted that menopausal status was rarely a stratification variable in major GLP-1 trials. The metabolic benefits of GLP-1 agonists, including reduced visceral fat and improved insulin sensitivity, are biologically plausible for this population. But "biologically plausible" and "proven best option" are not the same thing.

Lifestyle intervention, particularly resistance training combined with dietary changes, has strong dedicated evidence in menopausal women. The MONET study and work by Brochu et al. in Obesity (2009) showed meaningful visceral fat reduction without pharmacotherapy in this group. GLP-1s are a legitimate tool, but calling them the single best option ignores what the literature actually shows.

What did they get wrong (or right)?

She got the physiology right. Estrogen loss driving visceral fat accumulation, insulin resistance, and cardiovascular risk is textbook endocrinology backed by decades of data, including work from the SWAN cohort study published in journals like JAMA Internal Medicine.

She also gets credit for accurately characterizing the research gap. The honest acknowledgment that "there isn't any data studying these medications in this particular population" is more intellectually honest than most wellness content on this topic. That admission should have tempered the "hands down 100%" claim that came earlier in the same video. It did not.

The core problem is the logical inconsistency. You cannot cite a review that says we do not have enough evidence, and simultaneously declare GLP-1s the definitive best option. That is not how evidence-based medicine works. The claim is also potentially harmful because it may discourage women from pursuing evidence-backed lifestyle interventions or hormone therapy discussions with their physicians, both of which have meaningful data in this population.

What should you actually know?

If you are in perimenopause or menopause and considering a GLP-1 medication, here is what the actual evidence landscape looks like right now. GLP-1 receptor agonists like semaglutide and tirzepatide produce clinically meaningful weight loss and visceral fat reduction in mixed adult populations. There is reasonable biological rationale for benefit in menopausal women given the shared mechanisms of insulin resistance and adiposity. But no randomized controlled trial has been designed specifically for this population, and the risk-benefit profile in the context of estrogen deficiency has not been formally characterized.

Hormone therapy, depending on timing and individual risk profile, also has documented effects on visceral fat distribution in menopausal women, as reviewed by Santen et al. in Endocrine Reviews (2010). Combining approaches may make sense for some patients, but that is a conversation to have with a clinician who knows your full history, not a conclusion to draw from a TikTok video.

The "comment peptide" call to action at the end raises a separate concern. Compounded peptides are not equivalent to FDA-approved brand-name GLP-1 medications in terms of regulatory oversight, manufacturing standards, or clinical evidence. Anyone being directed toward compounded products should ask specific questions about sourcing and quality before proceeding.